

Curriculum Vitae

Informazioni personali

Nome / Cognome

Indirizzo(i)

Telefono(i)

Fax

E-mail

Cittadinanza

Data di nascita

Sesso

Settore professionale

Esperienza professionale

Date

Lavoro o posizione ricoperti

Principali attività e

responsabilità

Nome e indirizzo del datore di

Tipo di attività o settore

Esperienza professionale

Date

Lavoro o posizione ricoperti

Principali attività e

responsabilità

Nome e indirizzo del datore di

Tipo di attività o settore

Istruzione e formazione

Dichiarazione sostitutiva di certificazione e dichiarazione sostitutiva dell'atto di

notorietà ai sensi del D.P.R. 445/28.12.2000

Il sottoscritto Emanuele Montomoli nato a Siena il 26 Settembre 1968 residente in

Siena 53100, via dello scarpellino 3

consapevole delle responsabilità penali cui può andare incontro in caso di
dichiarazioni mendaci, ai sensi e per gli effetti di cui all'art. 76 del D.P.R.
445/2000 e sotto la propria responsabilità dichiara ai sensi dell'art. 46 e 47 del
DPR 445/2000

Emanuele Montomoli

/p Dip. Sanità Pubblica Università degli Studi di Siena, Via Aldo Moro 3 - 53100

Siena - ITALIA

+39 0577234134

+39 0577234090

emontomoli@montomoli.eu

Italiana

26 settembre 1968

maschio

Professore Associato – Università degli studi di Siena

Da 1 dicembre 2002 ad oggi

Professore Associato –

Responsabile di Unità di Ricerca

Università degli studi di Siena Via Banchi di Sotto 55 – Siena - Italia

Ricerca Scientifica, Formazione

Da 1 dicembre 1994 a 30 novembre 2002

Funzionario Tecnico

Procedure Tecniche in Laboratorio Biomedico

Università degli studi di Siena Via Banchi di Sotto 55 – Siena - Italia

Ricerca Scientifica

Firma

Allegati

Ulteriori informazioni

Patente

Patente categoria A e B

Allegato 1 "Pubblicazioni scientifiche"

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30
giugno 2003, n. 196 "Codice in materia di protezione dei dati personali
(facoltativo)".

1. Cellesi C, Sansoni A, Casini S, Migliorini L, Zaccchini F, Gasparini R, Montomoli E, Bonacci A, Bravi A. *Chlamydia pneumoniae and angiographically demonstrated coronary artery disease in sample population from Italy*. Atherosclerosis 1999 Jul; 145 (1): 81-5. **IF: 4.287**
2. Bonanni P, Colombai R, Gasparini R, Lo Nostro A, Tiscione E, Tomei A, Montomoli E, Comodo N. *Impact of routine infant and adolescent hepatitis B vaccination in Tuscany, Central Italy*. Pediatr Infect Dis J 1999 Aug; 18 (8): 677-82. **IF: 3.086**
3. Gasparini R, Pozzi E, Montomoli E, Fragaipane F, Senatore M, Minutello and A. Podda. *Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects*. Eur J Epidemiol. 2001;17(2):135-40. **IF: 1.727**
4. Fonzi M, Montomoli E, Gasparini R, Devanna D, Fonzi L. *Morpho Structural variations of bacterial spores after treatment in steam vacuum assisted autoclave*. Bull. Group. Int. Rech. Sci. Stomatol. Odontol. 41 (4), 124-130, 1999.
5. Oxford JS, Manuguerra C, Kistner O, Linde A, Kunze M, Lange W, Schweiger B, Spala G, Rebelo de Andrade H, Brena PR, Beytout J, Brydak L, Caraffa de Stefano D, Hungnes O, Kyncl J, Montomoli E, Gil de Miguel A, Vranckx R, Osterhaus A. *A new European perspective of influenza pandemic planning with a particular focus on the role of mammalian cell culture vaccines*. Vaccine. 2005, Sep 13. **IF: 3.377**
6. Mike M, Putz, Isabella Alberini, Claire M. Midgley, Iaria Manini, Emanuele Montomoli, and Geoffrey L. Smith. *Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy*. J Gen Virol 2005 86: 2955-2960. **IF: 3.120**
7. Rizzo C, Viboud C, Montomoli E, Simonsen L, Miller MA. *Influenza-related mortality in the Italian elderly: no decline associated with increasing vaccination coverage*. Vaccine. 2006 Oct 30;24(42-43):6468-75. **IF: 3.377**
8. Montomoli E, Manini I. *Pre-emptive vaccination against pandemic influenza virus*. Vaccine. 2007 Mar 1;25(11):1921-2. **IF: 3.377**
9. Valeria Alfonsi, Emanuele Montomoli, Iaria Manini, Isabella Alberini, Chiara Gentile, Maria Cristina Rota and Marta Luisa Ciofi degli Atti. *Susceptibility to varicella in childbearing age women, Central Italy: is there a need for vaccinating this population group?* Vaccine. 2007 Aug 10;25(32):6086-8. **IF: 3.377**
10. Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, Tavarini S, Scheffczik H, Uguzzoli M, Singh M, Kazaz J, Montomoli E, Del Giudice G, Rappuoli R, O'Hagan DT. *Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice*. Vaccine. 2008 Jan 24;26(4):552-61. **IF: 3.377**
11. Ansaldi F, Bacillieri S, Durando P, Sticchi L, Valle L, Montomoli E, Icardi G, Gasparini R, Crovari P. *Cross-protection by MF59trade mark-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses*. Vaccine. 2008 Mar 17;26(12):1525-9. **IF: 3.377**
12. Ehrlich HJ, Müller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Löw-Baselli A, Vartian N, Bobrovsky R, Pavlova BG, Pöllabauer EM, Kistner O, Barrett PN, Baxter HSN1 *Pandemic Influenza Vaccine Clinical Study Team. A clinical trial of a whole-virus HSN1 vaccine derived from cell culture*. N Engl J Med. 2008 Jun 12;358(24):2573-84; **IF: 52.589**.
13. Pippi F, Bracciale L, Stolzoli L, Giaccherini R, Montomoli E, Gentile C, Filletti S, De Luca A, Cellesi C. *Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania*. HIV Med. 2008 Jun 11; **IF: 3.347**
14. Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. *Safety, tolerability and immunogenicity of a mammalian cell culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial*. Vaccine 2009 Jan 29; 27 (5): 786-791 **IF: 3.377**
15. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecci L, di Giovanni P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A. *MF59-Adjuvanted HSN1 Vaccine Induces*

Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults. PLoSone February 2009; Volume 4; Issue 2. **IF: 4.351**

16. Burgassi S, Zaratelli V, Montomoli E, Bocci V. **How much ozone bactericidal activity is compromised by plasma components?** J Appl Microbiol. 2009 Feb 14; 1-7. **IF: 2.501.**

17. C Gentile, I Alberini, I Manini, S Rossi, E Montomoli, T Pozzi, C Rizzo, V Alfonsi. **Hepatitis a seroprevalence in Tuscany, Italy.** Eurosurveillance vol 14 (10) 12Mar2009.

18. Grazia Galli, Kathy Hancock, Katja Hoschler, Joshua Devos, Michaela Praus, Monica Bardelli, Carmine Malzone, Flora Castellino, Chiara Gentile, Teresa McNally, Giuseppe Del Giudice, Angelika Banzhoff, Volker Brauer, Emanuele Montomoli, Maria Zambon, Jacqueline Katz, Karl Nicholson, and Iain Stephenson. **Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.** Proc Natl Acad Sci U S A (PNAS); 2009 May 12;106(19):7962-7. **IF: 9.598.**

19. Isabella Alberini, Elena Del Tordello, Alba Fasolo, Nigel Temperton, Grazia Galli, Chiara Gentile, Emanuele Montomoli, Anne K. Hilbert, Angelika Banzhoff, Giuseppe Del Giudice, John Donnelly, Rino Rappuoli, Barbara Capecci. **Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses.** Vaccine. 2009 Oct 9;27(43):5998-6003. **IF: 3.377.**

20. Hartmut J. Ehrlich, Markus Müller, Sandor Fritsch, Markus Zeitlinger, Greg Beresuk, Alexandra Low-Baselli, Maikel V.W. van der Velden, Eva Maria Pollabauer, Friedrich Maritsch, Borislava G. Pavlova, Paul A. Tambyah, Helen M. L. Oh, Emanuele Montomoli, Otfried Kistner, and P. Noel Barrett. **A Cell Culture (Vero)-Derived H5N1 Whole-Virus Vaccine Induces Cross-Reactive Memory Responses.** J Infect Dis. 2009 Oct 1;200(7):1113-8. **IF: 6.035.**

21. Kunze U; ISW TBE. **Tick-borne encephalitis: from childhood to golden age does increased mobility mean increased risk? Conference report of the 11th meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE).** Vaccine. 2010 Jan 22;28(4):875-6. Epub 2009 Nov 27.

22. Dormitzer PR, Rappuoli R, Casini D, O'Hagan D, Runham C, Montomoli E, Baudner B, Donnelly JJ 3rd, Lappin G. **Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice.** PLoS Curr Influenza. 2009 Aug 31;RRN1025.

23. Rizzo C, Rota MC, Bella A, Alfonsi V, Declich S, Caporali MG, Ranzhiasi A, Lappin G, Piccirella S, Salmaso S, Montomoli E. **Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the pre-pandemic period.** Vaccine. 2010 Apr 30;28(20):3558-62. Epub 2010 Mar 20. **IF: 3.616.**

24. Ansaldi F, Zancolli M, Durando P, Montomoli E, Sticchi L, Del Giudice G, Icardi G. **Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.** Vaccine. 2010 Jun 7;28(25):4123-9. Epub 2010 Apr 28. **IF: 3.616.**

25. Fraga E, Gasparini R, Schioppa F, Laghi-Pasini F, Montomoli E, Banzhoff A. **A Heterologous MF59-Adjuvanted H5N1 Prepandemic Influenza Booster Vaccine Induces a Robust, Cross-Reactive Immune Response in Adults and the Elderly.** Clin Vaccine Immunol. 2010 Nov;17(11):1817-9. Epub 2010 Sep 1. **IF: 2.373.**

26. Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, Clemens R. **Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.** Pediatrics. 2010 Oct;126(4):e762-70. Epub 2010 Sep 6. **IF: 4.687.**

27. Landry N, Ward BJ, Trépanier S, Montomoli E, Dargis M, Lapin G, Vézina LP. **Preliminary and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza.** PLoS One. 2010 Dec 22;5(12):e15559. **IF: 4.351**

28. Wood JM, Montomoli E, Newman RW, Daas A, Buchheit KH, Terao E. **Collaborative study on influenza vaccine clinical trial serology - part 2: reproducibility study.** Pharmeur Bio Sci Notes. 2011 Jun;2011(1):36-54.

29. Svindland SC, Jul-Larsen A, Pathirana R, Andersen S, Madhuan A, Montomoli E, Jabbal-Gill I, Cox RJ. **The H5N1 vaccine. Influenza Other Respi Viruses.** 2011 Jul 12. **IF: 4.157**

30. Montomoli E, Piccirella S, Khadang B, Mennitto E, Camerini R, De Rosa A. **Current adjuvants and new perspectives in vaccine formulation.** Expert Rev Vaccines. 2011 Jul;10(7):1053-61. **IF: 4.145.**

31. Carraro G, Naso A, Montomoli E, Gasparini R, Camerini R, Panatto D, Tineo MC, De Giorgi L, Piccirella S, Khadang B, Ceracchi M, De Rosa A. *Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvanted pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study.* Vaccine. 2012 Feb 1;30(6):1170-80. **IF: 3.572**
32. Faenzi E, Zedda L, Bardelli M, Spensieri F, Borgogni E, Volpini G, Buricchi F, Pasini FL, Capecechi PL, Montanaro F, Belli R, Lattanzi M, Piccirella S, Montomoli E, Ahmed SS, Rappuoli R, Del Giudice G, Finco O, Castellino F, Galli G. *One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies.* Vaccine. 2012 Jun 8;30(27):4086-94. **IF: 3.572**
33. Jul-Larsen A, Madhun A, Brokstad K, Montomoli E, Yusibov V, Cox R. *The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants.* Hum Vaccin Immunother. 2012 May 1;8(5). **IF: 3.577**
34. Lunelli A, Rizzo C, Puzelli S, Bella A, Montomoli E, Rota MC, Donatelli I, Pugliese A. *Understanding the dynamics of seasonal influenza in Italy: incidence, transmissibility and population susceptibility in a 9-year period.* Influenza Other Respi Viruses. 2012 Jun 14. **IF: 4.157.**
35. Montomoli E, Khadang B, Piccirella S, Trombetta C, Mennitto E, Manini I, Stanzani V, Lapini G. *Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.* Expert Rev Vaccines. 2012 May;11(5):587-94. **IF: 4.145.**
36. Svindland SC, Pedersen GK, Pathirana RD, Bredholt G, Nøstbakken JK, Jul-Larsen A, Guzmán CA, Montomoli E, Lapini G, Piccirella S, Jabbal-Gill I, Hinichcliffe M, Cox RJ. *A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine.* Influenza Other Respi Viruses. 2012 Nov 21. **IF: 4.157.**